Compare · MAMO vs STE
MAMO vs STE
Side-by-side comparison of Massimo Group (MAMO) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- MAMO operates in Consumer Discretionary, while STE operates in Health Care - the two are in different parts of the market.
- STE is the larger of the two at $20.50B, about 502.0x MAMO ($40.8M).
- Over the past year, MAMO is down 57.4% and STE is down 13.5% - STE leads by 43.9 points.
- STE has been more active in the news (39 items in the past 4 weeks vs 2 for MAMO).
- STE has more recent analyst coverage (16 ratings vs 0 for MAMO).
- Company
- Massimo Group
- STERIS plc (Ireland)
- Price
- $0.98+2.23%
- $210.04-1.01%
- Market cap
- $40.8M
- $20.50B
- 1M return
- +3.31%
- -1.87%
- 1Y return
- -57.42%
- -13.48%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 2
- 39
- Recent ratings
- 0
- 16
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest MAMO
- SEC Form 8-K filed by Massimo Group
- Massimo Group Begins Revenue-Generating Fulfillment for Large-Scale Tractor Supply Retail Program
- SEC Form 10-Q filed by Massimo Group
- SEC Form DEF 14A filed by Massimo Group
- Massimo Motor Accelerates Fleet Expansion; Strong Demand for HVAC-Equipped Utility Platforms at NAFA 2026
- Massimo Expands Fleet Network and Advances Second-Generation Autonomous Patrol Platform
- Massimo Group Announces CEO Appointment and Executive Chairman Transition
- Massimo Group filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Massimo Group Reports FY2025 Results, Delivers Margin Expansion and Advances Premium Product Pipeline
- Massimo Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 90 units of Ordinary Shares, decreasing direct ownership by 0.68% to 13,184 units (SEC Form 4)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)